Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. Our lead product candidate is CAVATAK®, a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21, now being evaluated in multiple clinical trials. CAVATAK binds to specific receptor proteins highly expressed on a...
Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. Our lead product candidate is CAVATAK®, a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21, now being evaluated in multiple clinical trials. CAVATAK binds to specific receptor proteins highly expressed on a range of tumour cell types, and acts to destroy local as well as metastatic cancer cells through cell lysis and the potential generation of a specific immune response against the cancer cells.
Upgrade this company profile// Update & customize all content. Ask PharmaCompass, click HERE.